Geron Corporation (GERN)
Geron Stock Rallies More Than 60% in a Year: Here's Why
FDA's approval of GERN's Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.
Geron: A Strong Launch And Financial Deals Make It Attractive
Geron exceeded expectations with $28.2mn in Q1 revenue, surpassing analyst estimates and showcasing strong physician feedback and market potential for imetelstat. Analysts are bullish, with H.C. Wainwright, Leerink, and Goldman Sachs projecting significant sales growth and maintaining high price targets for Geron. Favorable funding deals with Royalty Pharma and Pharmakon Advisors provide $375mn, enhancing Geron's financial stability and supporting future commercialization efforts.
Geron: A Post Earnings And Funding Announcement Assessment
Geron Corporation's imetelstat, now branded as Rytelo, was finally approved by the FDA in June for treating lower risk myelodysplastic syndromes and has shown solid initial sales traction. The company just reported third quarter results and announced a new financing arrangement. Analyst firms are positive on the company's prospects. An updated analysis of Geron Corporation follows in the paragraphs below.
Geron Corporation (GERN) Q3 2024 Earnings Call Transcript
Geron Corporation (NASDAQ:GERN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Aron Feingold - Vice President of IR and Corporate Communication John Scarlett - Chairman and CEO Jim Ziegler - EVP and CCO Michelle Robertson - EVP and CFO Faye Feller - EVP, CMO Andrew Grethlein - EVP, COO Conference Call Participants Tara Bancroft - T. D. Cowen Faisal Khurshid - Leerink Partners Corinne Johnson - Goldman Sachs Carter Gould - Barclays Emily Bodnar - H.C.
Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.
Geron: Derisked And Highly Attractive After Approval
Geron's imetelstat (Rytelo) received FDA approval for MDS, marking a significant milestone despite past setbacks and negative comments from the FDA. Imetelstat, a telomerase inhibitor, shows promise in treating MDS and MF, with significant clinical trial results and manageable adverse events. Geron's financials are strong with a $2.8bn market cap and cash runway until 2026, positioning it well for future growth.
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.09 per share a year ago.
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
Is Geron Stock a Buy Following Its First New Drug Approval?
The U.S. Food and Drug Administration approved Geron's lead candidate on June 6, under the brand name Rytelo. Peak Rytelo sales could surpass $1 billion annually.
Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers
Geron (GERN) shares skyrocketed over 19% in intraday trading Friday after the Food and Drug Administration (FDA) approved the biopharma company's drug Rytelo for those with rare blood cancers.
Geron Corporation: FDA Approval Fuels Stock Price Surge
The recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation NASDAQ: GERN into the spotlight, sparking a surge in Geron's stock price and attracting heightened attention from investors seeking opportunities within the healthcare sector and biotech sector. This momentous achievement marks a turning point for Geron and underscores the company's commitment to developing innovative therapies for complex diseases.
Why Is Geron (GERN) Stock Up 18% Today?
Geron (NASDAQ: GERN ) stock is heading higher on Friday after getting approval from the Food and Drug Administration (FDA) for RYTELO. RYTELO is the company's “adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent ( TD ) anemia.
